The mission of START is to accelerate the development of new anticancer drugs that will improve the quality of life and survival for patients with cancer. Our drug development program is not only furthering cancer research, but also offers hope to patients facing the toughest cancer battles.
Phase I is the most important step in the development of a new drug or therapy. During this phase, a treatment’s safety, dosage, and side effects are determined. Phase I trials involve a small number of patients (20-80) for whom standard therapies have proven ineffective or for whom alternative therapies are unavailable. Prior to being tested in a Phase I trial, a treatment has been tested at length in the lab on animals, and the drug has been deemed safe for use in humans. While Phase I trials may be beneficial for patients, their primary goals are to determine a drug’s safety and adequate dosing and schedule of administration. These trials often involve blood or tissue testing to evaluate the drug’s mechanism of action and pharmacology.
START Midwest conducts all types of early clinical drug development trials with the highest standards. Types of Phase I studies conducted at START Midwest include:
- Phase I first in human and first in class
- Tumor-type directed Phase Ib
- Drug-drug interaction and pharmacology studies
- Targeted therapy for mutation-selected populations